Office workstation top view of business people working around M&A, keyboard, calculator, phablet and money on wooden table - merger and acquisition concept

Alexion said that the deal would help it diversify beyond the complement C5 inhibitors like Soliris that have been its primary cash cow. Portola markets drugs for coagulation-related disorders and is also developing a drug for T- and B-cell lymphomas.

LEAVE A REPLY

Please enter your comment!
Please enter your name here